Hypereosinophilic syndrome
MONDO:0015691Hypereosinophilic syndrome (HES) constitutes a rare and heterogeneous group of disorders, defined as persistent and marked blood eosinophilia and/or tissue eosinophilia associated with a wide range of clinical manifestations reflecting eosinophil-induced tissue/organ damage.
Also known as: HES, hypereosinophilic disease, hypereosinophilic disorder, hypereosinophilic syndrome, eosinophilia
54 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Smart inhalers track Fasenra's asthma control over full dosing cycle
Disease control Not yet recruitingThis study tracks people with severe eosinophilic asthma who already take Fasenra (benralizumab) every 8 weeks. Participants use electronic monitors on their regular inhalers and a study-provided rescue inhaler (AirSupra) to see if asthma control stays steady throughout the dosin…
Phase: PHASE4 • Sponsor: Endeavor Health • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New asthma shot could help kids breathe easier
Disease control Not yet recruitingThis study tests a new injectable drug called depemokimab in 30 children aged 6 to 11 with asthma that involves a specific type of inflammation. The drug is given alongside their usual asthma medicines to see how the body processes it, how well it works, and if it is safe. The go…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Roll-Over study offers continued benralizumab access for patients who benefit
Disease control Not yet recruitingThis study gives ongoing access to benralizumab (Fasenra) for people with asthma, eosinophilic granulomatosis with polyangiitis (EGPA), or hypereosinophilic syndrome (HES) who completed a prior benralizumab trial and still benefit from the drug. About 230 participants will receiv…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Nasal spray could tame tough asthma Flare-Ups
Disease control Not yet recruitingThis Phase 2 trial tests AD17002, a nasal spray that aims to calm the immune system in people with moderate to severe eosinophilic asthma that is not well controlled by current treatments. About 126 adults will receive either the spray or a placebo for 3 months. Researchers will …
Phase: PHASE2 • Sponsor: Advagene Biopharma Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Hope for severe asthma: study tests if biologics can heal lungs
Knowledge-focused Not yet recruitingThis study looks at whether biologic therapy can reverse long-term lung damage in adults with severe asthma. Researchers will follow 150 patients and 50 healthy volunteers for two years, using advanced imaging and lung function tests. The goal is to see if treatment leads to 'cli…
Phase: NA • Sponsor: Western University, Canada • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC